Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2020 09:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases

Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatmentsOliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet...
September 29, 2020 15:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going...
September 24, 2020 21:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

SUWON, Republic of Korea, Sept. 24, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today the submission of an...
September 15, 2020 22:30 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Presents New Data on Asymmetric siRNA Therapy at TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference

SUWON, Korea, Sept. 15, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented a poster at the TIDES: Oligonucleotides and...
July 09, 2020 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present at Global RNAi-Based Therapeutics Summit

SUWON, Republic of Korea, July 09, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder...
June 16, 2020 10:00 ET | Source: OliX Pharmaceuticals; LGC Biosearch Technologies Inc.

OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

SUWON, Republic of Korea and LONDON, June 16, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company signed...
May 20, 2020 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Presents at BIO KOREA 2020 International Convention

SUWON, Republic of Korea, May 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced that Dong-Ki Lee, Ph.D.,...
April 17, 2020 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Expands Scientific Advisory Board with Addition of Leading Liver Experts

SUWON, Republic of Korea, April 17, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced the appointment of Dr....
March 30, 2020 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals and AM Chemicals Announce Exclusive Licensing and Supply Agreement for GalNAc-Conjugation Technology for Liver Targeting

OliX Pharmaceuticals to accelerate the development of effective targeted therapy for liver diseases using AM Chemical’s GalNAc-conjugation technology SUWON, Republic of Korea, March 30, 2020 (GLOBE...
March 20, 2020 10:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs

OliX has been developing novel delivery approaches for siRNAs to the lung tissueOliX’s local pulmonary administration of siRNA drugs through nebulization may contribute to improved treatment...